Sergey V Glagolev

Sergey V Glagolev

Auto-generated profile, based on publicly available information

Sergey V Glagolev

Ministry of Health of the Russian Federation

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2023 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
NSNatalia Shatalova
Natalia Shatalova
DSDmitry Sychev
Dmitry Sychev
KMK. B. Mirzaev
K. B. Mirzaev
AKA. I. Kochetkov
A. I. Kochetkov
EEE. Yu. Ebzeeva
E. Yu. Ebzeeva
SGS. V. Glagolev
S. V. Glagolev
Aim. To study the possible relationship between polymorphic variants of ABCB1 (rs2032582, rs1045642, rs1128503), CYP3A5 (rs776746), CYP3A4 (rs35599367) and CYP2J2 (rs890293) genes with residual equilibrium concentrations (Cmin,ss) of rivaroxaban in patients with non-valvular atrial fibrillation (AF) and stage 3 and 4 chronic kidney disease (CKD).Material and methods. A total of 123 patients 52 to 97 years old (median age, 82 years) with AF in combination with stage 3 and 4 CKD were included in the study. Each patient underwent a pharmacogenetic and pharmacokinetic study.Results. Cmin,ss and dose-adjusted concentration (Cmin,ss/D) of rivaroxaban were significantly higher in patients with the TT genotype than with the CT genotype of the polymorphic variant rs1045642 of the ABCB1 gene (Сmin,ss 60,5 [36,7;173] ng/ml and 54,8 [23,1;97,3] ng/ml, respectively, р=0,016; Сmin,ss/D 4,06[2,3;8,1] ng/ml/mg and 2,2 [1,1;4,9] ng/ml/mg, р=0,006). In patients with the T allele (CT and TT genotypes), compared with CC genotype carriers, Cmin,ss and Cmin,ss/D were significantly higher (Cmin,ss 60,5 [36,7;173] ng/ml and 45,8 [20,9;82,3] ng/ml, respectively, p=0,029; Cmin,ss/D 4,06 [2,3;8,1] ng/ml/ mg and 2,6 [1,2;4,8] ng/ml/mg, respectively, p=0,014). Also, Cmin,ss and Cmin,ss/D was significantly higher in patients with the TT genotype according to the polymorphic variant rs2032582 of the ABCB1 gene than in patients with the GG genotype (p=0,02 and р=0,016 respectively). Cmin,ss and Cmin,ss/D in T allele (GT and TT genotypes) carriers were significantly higher than in T allele homozygotes (Cmin,ss 57,1 [27,7;106,0] ng/ml versus 37,6 [18,6;61,7] ng/ml respectively, p=0,024; Cmin,ss/D 3,6 [1,7;7,4] ng/ml/mg versus 2,3 [1,1;4,09] ng/ml/mg respectively, p=0,032). Differences in Сmin,ss and Сmin,ss/D of rivaroxaban were detected when comparing TC, CC and TT genotypes of polymorphism rs1128503 of the ABCB1 gene. When comparing Сmin,ss and Сmin,ss/D of rivaroxaban among carriers of AG and GG genotypes of the rs776746 polymorphism of the CYP3A56986A>G gene, no significance was detected (p>0,05). Also, no difference in Cmin,ss and Cmin,ss/D was found when comparing carriers of the CC and CT genotypes of the rs35599367 polymorphism of the CYP3A4 gene, and carriers of the CC and AC genotypes of the rs890293 polymorphism of the CYP2J2 gene (p>0,05).Conclusion. The carriage of T allele by polymorphic variants rs1045642 and rs2032582 of the ABCB1 gene affects Cmin,ss and Cmin,ss/D of rivaroxaban.

1 October 2025 in Science Progress
Verified
Journal Article
Open access
DSDmitry Sychev
Dmitry Sychev
Anastasiia BuianovaAnastasiia Buianova
Anastasiia Buianova
SASherzod P Abdullaev
Sherzod P Abdullaev
KMKarin B Mirzaev
Karin B Mirzaev
VBVera Belova
Vera Belova
DKDmitriy Korostin
Dmitriy Korostin
Background: Direct oral anticoagulants (DOACs) are first-line medications for stroke prevention in non-valvular atrial fibrillation (AF). However, variability in drug response poses risks of hemorrhagic or thromboembolic events. Objectives: Although genetic influences on DOACs safety are increasingly recognized, robust evidence directly linking specific polymorphisms to bleeding risk remains limited. Design: Multi-center observational case–control study including exome-wide association analysis of 196 non-valvular AF patients treated with rivaroxaban or apixaban, comprising 97 with bleeding complications and 99 without. Methods: DOAC plasma concentrations, urinary 6-β-hydroxycortisol and cortisol levels were measured for CYP3A4 phenotyping. Sequencing was performed on the DNBSEQ G-400 platform. Single-nucleotide variant (SNV) associations with bleeding risk were assessed using logistic regression with additive, dominant, and recessive genetic models. Polygenic risk scores (PRSs) were calculated to evaluate cumulative genetic effects. Results: No SNVs reached Bonferroni-corrected significance under any model. PRSs showed weak predictive ability for bleeding with apixaban. For rivaroxaban, regression indicated that ln C ss min /D + 1 index increased with PRS, age, and 6-β-hydroxycortisol/cortisol ratio, but decreased with higher 6-β-hydroxycortisol and coronary heart disease presence. No statistically significant differences were found for the PharmGKB Level 3 variants rs1045642 (rivaroxaban) and rs2231142 (apixaban). Trends toward statistical significance were observed for the rs2472304-G variant in rivaroxaban users, rs6977165-C in apixaban users, and for the CYP3A4*1/*36 diplotype. Conclusion: Residual equilibrium concentration of DOACs, including dose-adjusted, did not independently predict bleeding risk in non-valvular AF patients. Variants rs2472304 and rs6977165 may warrant further investigation as potential contributors to bleeding risk.

30 January 2024 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
AMA. V. Matveev
A. V. Matveev
SGS. V. Glagolev
S. V. Glagolev
KKK. N. Koryanova
K. N. Koryanova
DSDmitry Sychev
Dmitry Sychev
The aim of the study was to investigate the dynamics of inpatient consumption of direct oral anticoagulants in different regions of the Russian Federation for the period from 2017 to 2022.Materials and methods. This study is a non-interventional, retrospective analysis of the electronic database records of Cursor Marketing LLC (Russia) about the announced by medical organizations and executed contracts for the purchase of direct oral anticoagulants (DOACs). The сonsumption was calculated on the basis of a DDD (defined-daily-dose) and estimated DDDTID (defined-daily-dose/1000-inhabitants/day) for each DOACs: rivaroxaban, dabigatran and apixaban. The Rosstat database available on its official website were used as a source of inhabitants data for the Russian regions.Results. A total of 57 866 records were entered into the analyzed databases of Cursor Marketing LLC (Russia) from 2017 to 2022, 47.38% of which indicated rivaroxaban as the drug being procured, 26.51% indicated dabigatran, and 26.11% indicated apixaban. Edoxaban was not procured by healthcare organizations. During the period investigated, there was an increase in the consumption of all DOACs studied, with a higher increase for apixaban (by an average of 284.6% per year), then rivaroxaban (by 144.8% per year) and, to a lesser extent, dabigatran (by 92.5% per year). The analysis of DOACs consumption in general showed that compared to 2017, the need for these drugs in medical organizations in 2022 increased by 18 times. The Urals Federal District consistently exceeds the national average in terms of DDTID consumption. Noteworthy is the consumption dynamics of the regions of the Central Federal District and the North-Western Federal District, which made it possible to achieve DDDTID values above the national average for 5 out of 6 observation years. The lowest rates of DOACs consumption were observed in the Volga Federal District, which, despite positive growth dynamics, failed to reach the national average values. A high level of consumption (>10 DDDTID) of rivaroxaban was noted for the Arkhangelsk region (2018) and the Nenets Autonomous District (in 2021), dabigatran – only for the Arkhangelsk region (in 2018). Many more regions reached high levels of the apixaban consumption, especially in 2021.Conclusion. Despite a number of limitations, the data on the volume of DOACs procurement can be used in the analysis of the consumption at both regional and national levels. When analyzing the DOACs consumption, the impact of COVID-19 pandemic and pharmacogenetic features of patients in different regions should be taken into account. During the studied period of time, a significant part of the Russian regions achieved a consumption level of rivaroxaban and apixaban, but not dabigatran, exceeding 1 DDDTID.

24 June 2025 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
NTN. V. Tereshkina
N. V. Tereshkina
NVN. Yu. Velts
N. Yu. Velts
EZE. O. Zhuravleva
E. O. Zhuravleva
GKG. V. Kutekhova
G. V. Kutekhova
SGS. V. Glagolev
S. V. Glagolev
НВН. Ю. Вельц
Н. Ю. Вельц
INTRODUCTION. Geriatric patients are the fastest growing demographic group, accounting for over half of all medicinal product users. Pharmacovigilance in this population is influenced by age-related physiological changes and social factors. Risk management plans (RMPs), developed by marketing authorisation holders, play a preventive role in managing the risks associated with the use of medicinal products in elderly patients.AIM. This study aimed to evaluate the completeness of information on the geriatric group within target populations in RMPs for medicinal products launched in the Russian pharmaceutical market in 2024.MATERIALS AND METHODS. This study analysed 110 RMPs for medicinal products potentially applicable to geriatric populations, submitted to the Scientific Centre for Expert Evaluation of Medicinal Products between January and December 2024. All the documents included full modules and sections.RESULTS. The analysis revealed critical gaps in RMPs data for geriatric populations, including the epidemiology of indication(s) and target population(s) (these data were missing in 52.0% of cases); clinical trial exposure (patients over 60 years were excluded from clinical trials in 47.3% of cases); populations not studied in clinical trials (these data were unreported in 63.6% of cases); post-authorisation experience in elderly or senile patients (these data were missing in 83.6% of cases); and potential harm from overdose (risk warnings were absent in 96.4% of cases). There were no additional risk minimisation measures for emphasising the considerations for medicinal product use in the geriatric population in the analysed documents.CONCLUSIONS. When drafting RMPs, marketing authorisation holders and medicinal product developers do not pay sufficient attention to geriatric populations and often underestimate the risks associated with medicinal product use in elderly and senile patients. The issues associated with the use of medicinal products in geriatric patients can be mitigated through rigorous risk management practices applied during pharmacotherapy. The parties concerned should consider this when drafting the summary of medicinal product characteristics and the patient information leaflet, labelling the medicinal product, and selecting the package size.